natgillin/translations-raw huggingface dataset:
Common: the following may affect up to 1 in 10 people - a change in the salt level in your blood shown in blood tests - signs include feeling confused or weak - abnormal skin sensations, such as numbness, tingling, itching, creeping, pricking or burning - headache - low potassium levels - shown up in blood tests - low magnesium levels - shown up in blood tests - high blood pressure - loss of appetite, stomach pain or upset stomach, passing wind, dry mouth, changes in your taste - heartburn (a burning sensation in the chest rising up to the throat) - low levels of “neutrophils” a type of white blood cell (neutropenia) -this can make you more likely to get infections and be shown up in blood tests - fever - feeling weak, dizzy, tired or sleepy - rash - itching - constipation - rectal discomfort 
- glavobol - nizka koncentracija kalija - pokaže se na preiskavah krvi - nizka koncentracija magnezija - pokaže se na preiskavah krvi - visok krvni tlak - izguba apetita, bolečine v želodcu ali razdražen želodec, vetrovi, suha usta, spremembe okusa
Moreover, sparse PK samples were collected at several days during steady state before the next dose (Cmin) for a larger subject population. 
Poleg tega so redko razporejenefarmakokinetične vzorce odvzeli ob več dneh v stanju dinamičnega ravnovesja pred naslednjim odmerkom (Cmin) zavečjo populacijo preiskovancev.Na podlagi povprečnihkoncentracij Cminje bilomogoče za 186 preiskovancev, ki so prejemali 300mg,izračunatipredvidenopovprečno koncentracijo (Cav).
If it is considered that co-administration is unavoidable, then it is recommended that the dose of sirolimus should be greatly reduced at the time of initiation of posaconazole therapy and that there should be very frequent monitoring of trough concentrations of sirolimus in whole blood. 
Učinek posakonazola na sirolimus pri bolnikih ni znan, vendar je treba pričakovati, da jespremenljiv zaradi spremenljive izpostavljenosti posakonazolumedbolniki.Sočasnauporabaposakonazola s sirolimusom ni priporočljiva in se ji je treba izogniti, če jele mogoče.Česesočasniuporabi ni mogoče izogniti, je ob uvedbi zdravljenja s posakonazolom priporočljivo zelo zmanjšati odmerek sirolimusa in zelo pogosto preverjati najnižjo koncentracijo sirolimusa v polni krvi.
No dose adjustment is recommended for patients with mild to severe hepatic impairment but caution is advised due to the potential for higher plasma exposure. 
Eliminacijski razpolovni čas (t1/2) se jev zadevnih skupinah podaljšal s približno 27 urnavsedopribližno43ur.Bolnikom z blagodohudookvaro jeter odmerka sicer ni trebaprilagoditi, a je zaradi možne večje plazemske izpostavljenosti priporočljiva previdnost.
Vascular disorders Common: 
Žilne bolezni Pogosti:
hepatic failure, hepatitis cholestatic, hepatosplenomegaly, liver tenderness, asterixis Skin and subcutaneous tissue disorders Common: 
odpoved jeter, holestatski hepatitis, hepatosplenomegalija,
See also below regarding the effect of posaconazole on rifabutin plasma levels. 
Glede vpliva posakonazola na koncentracijerifabutina vplazmi glejtetudispodaj.
Gastrointestinal disorders Very Common: 
Bolezni prebavil Zelo pogosti:
− sudden, severe allergic reaction. 
- nenadna, huda alergijska reakcija.
In the absence of compatibility studies, INTEGRILIN must not be mixed with other medicinal products except those mentioned in 6.6. 
Zaradi pomanjkanja študij kompatibilnosti zdravila INTEGRILIN ne smemo mešati z drugimi zdravili, razen s tistimi, ki so našteta v poglavju 6.6.
− Integrilin is not intended for use in children or adolescents less than 18 years of age. 
− Zdravilo Integrilin ni namenjeno za uporabo pri otrocih in mladostnikih do 18. leta starosti.
INTEGRILIN is not compatible with furosemide. 
INTEGRILIN ni združljiv s furosemidom.
− if you have been treated with another medicine of the same type as Integrilin. 
− če ste bili zdravljeni z drugim zdravilom iste vrste, kot je Integrilin.
Eptifibatide p-Value 
Eptifibatid vrednost p
− anaemia (decreased number of red blood cells). 
- anemija (zmanjšano število rdečih krvnih celic).
What Integrilin is and what it is used for 
Kaj je zdravilo Integrilin in za kaj ga uporabljamo
According to epidemiological findings, a higher incidence of cardiovascular events has been associated with certain indicators, for instance: 
Po epidemioloških izsledkih je večja incidenca kardiovaskularnih pojavov povezana z določenimi pokazatelji, npr.: - starostjo,
Other medicines and Integrilin 
Druga zdravila in zdravilo Integrilin
Integrilin is not usually recommended for use during pregnancy. 
Zdravila Integrilin po navadi ni priporočljivo uporabljati med nosečnostjo.
− Before and during your treatment with Integrilin, samples of your blood will be tested as a safety measure to limit the possibility of unexpected bleeding. 
− Pred in med zdravljenjem z zdravilom Integrilin bodo pri vas opravili krvne preiskave kot varnostni ukrep za zmanjšanje možnosti za pojav nepričakovanih krvavitev.
INTEGRILIN should not be used during pregnancy unless clearly necessary. 
Zdravila INTEGRILIN ne smete uporabljati med nosečnostjo, razen če je nujno potrebno.
− During use of Integrilin, you will be checked carefully for any signs of unusual or unexpected bleeding. 
− Med uporabo zdravila Integrilin vas bodo skrbno spremljali, da ugotovijo morebitne znake nenavadne ali nepričakovane krvavitve.
− Integrilin is recommended for use only in adult, hospitalised patients in coronary care units. 
− Zdravilo Integrilin priporočamo za uporabo le pri odraslih bolnikih, hospitaliziranih na bolnišničnih koronarnih oddelkih.
INTEGRILIN-treated patients who had a prothrombin time (PT) > 14.5 seconds and received warfarin concomitantly did not appear to be at an increased risk of bleeding. 
Tudi pri z zdravilom INTEGRILIN zdravljenih bolnikih, ki so imeli protrombinski čas (PČ) > 14,5 sekund in so sočasno prejemali varfarin, ni kazalo, da bi bili bolj ogroženi zaradi krvavitev.
What Integrilin is and what it is used for What you need to know before you are given Integrilin How to use Integrilin 
Kaj je zdravilo Integrilin in za kaj ga uporabljamo Kaj morate vedeti, preden boste dobili zdravilo Integrilin Kako uporabljati zdravilo Integrilin
Date of latest renewal: 09.07.2009 
Datum prve odobritve: 01.07.1999 Datum zadnjega podaljšanja: 09.07.2009
You must not be given Integrilin: − if you are allergic to eptifibatide or any of the other ingredients of this medicine (listed in section 
− če ste alergični na eptifibatid ali katerokoli drugo sestavino tega zdravila (navedeno v poglavju
Please refer to the Normosol R Summary of Product Characteristics for details on its composition. 
glejte Povzetek glavnih značilnosti zdravila Normosol R za podrobnosti o njegovi sestavi.
There were no notable differences observed with GUSTO severe bleeding rates. 
Pri deležih hudih krvavitev GUSTO ni bilo opaznih razlik.
Frequencies are defined as very common (≥1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000). 
Pogostnosti so opredeljene kot: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000).
Blood and Lymphatic System Disorder 
Bolezni krvi in limfatičnega sistema
INTEGRILIN is also intended for concurrent use with acetylsalicylic acid, as it is part of standard management of patients with acute coronary syndromes, unless its use is contraindicated. 
Zdravilo INTEGRILIN je namenjeno tudi za sočasno uporabo z acetilsalicilno kislino, ker je del standardne sheme vodenja bolnikov z akutnim koronarnim sindromom, če zanj ni kontraindikacij.
− marked ECG changes (in particular ST-segment abnormalities) 
- izrazitimi spremembami v EKG (zlasti z nepravilnostmi spojnice ST),
− known history of intracranial disease (neoplasm, arteriovenous malformation, aneurysm) 
- znano anamnezo intrakranialne bolezni (neoplazme, arteriovenske malformacije, anevrizme);
The mechanism, whether immune- and/or non-immune-mediated, by which eptifibatide may induce thrombocytopaenia is not fully understood. 
Mehanizem - imunski in/ali neimunski - po katerem lahko eptifibatid povzroči trombocitopenijo, ni povsem pojasnjen.
PURSUIT trial 
Študija PURSUIT
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent published on the European medicines web-portal. 
Zahteve glede predložitve rednega posodobljenega poročila o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov EU (seznamu EURD), opredeljenem v členu 107c(7)
INTEGRILIN infusion should be stopped immediately if circumstances arise that necessitate thrombolytic therapy or if the patient must undergo an emergency CABG surgery or requires an intraortic balloon pump. 
Infuzijo zdravila INTEGRILIN morate nemudoma ustaviti, če nastopijo okoliščine, ki zahtevajo trombolitično zdravljenje, če mora bolnik na nujen koronarni premostitveni poseg ali če potrebuje intraaortno balonsko črpalko.
Your doctor will weigh up the benefit to you against the risk to your baby of using Integrilin while you are pregnant. 
Zdravnik bo pretehtal koristi, ki jih uporaba zdravila Integrilin med nosečnostjo pomeni za vas, v primerjavi s tveganjem, ki ga pomeni za otroka.
GUSTO severe/life threatening bleeding was uncommon and comparable in both treatment groups (0.8%). 
Hude/smrtno nevarne krvavitve po GUSTO so bile občasne in v obeh terapevtskih skupinah primerljive (0,8 %).
Patients could be enrolled only if they had experienced cardiac ischemia at rest (≥ 10 minutes) within the previous 24 hours and had: 
Bolniki so bili lahko v to študijo vključeni le, če so imeli v preteklih 24 urah ishemijo miokarda v mirovanju (≥ 10 minut) in:
If serious bleeding occurs that is not controllable with pressure, the INTEGRILIN infusion should be stopped immediately and any unfractionated heparin that is given concomitantly. 
Če se pojavi hujša krvavitev, ki je ni mogoče obvladati s pritiskom, morate nemudoma ustaviti infuzijo zdravila INTEGRILIN in morebitno sočasno uporabo nefrakcioniranega heparina.
In the same population, plasma elimination half-life is approximately 2.5 hours, plasma clearance 55 to 80 ml/kg/hr and volume of distribution of approximately 185 to 260 ml/kg. 
V isti populaciji je razpolovni čas eliminacije zdravila iz plazme približno 2,5 ur, plazemski očistek od 55 do 80 ml/kg/h, porazdelitveni volumen pa približno 185 do 260 ml/kg.
Cardiac arrest, ventricular fibrillation, ventricular tachycardia, congestive heart failure, atrioventricular block, atrial fibrillation. 
Pogosti srčni zastoj, ventrikularna fibrilacija, ventrikularna tahikardija, kongestivno srčno popuščanje, atrioventrikularni blok, atrijska fibrilacija
ESPRIT: This was a double-blind, multicentre, randomised, parallel-group, placebo-controlled trial evaluating the safety and efficacy of eptifibatide therapy in patients scheduled to undergo nonemergent percutaneous coronary intervention (PCI) with stent implantation. 
ESPRIT: To je bila dvojno slepa, multicentrična, randomizirana, s placebom kontrolirana študija vzporednih skupin za oceno varnosti in učinkovitosti zdravljenja z eptifibatidom pri bolnikih s predvideno neurgentno perkutano koronarno intervencijo (PCI) z namestitvijo žilne opornice.
Glaxo Operations UK Ltd., (Trading as Glaxo Wellcome Operations), Harmire Road, Barnard Castle, Co. Durham, DL12 8DT, United Kingdom 
Glaxo Operations UK Ltd., (Trading as Glaxo Wellcome Operations), Harmire Road, Barnard Castle, Co.Durham, DL12 8DT, Velika Britanija
− reduced blood flow to the brain. 
- zmanjšana prekrvavitev možganov.
The need for blood transfusions was increased modestly by Integrilin treatment (11.8% versus 9.3% for placebo). 
Zdravljenje z zdravilom Integrilin je zmerno povečalo potrebo po transfuzijah krvi (11,8 % v primerjavi z 9,3 % pri placebu).
Consequently the use of INTEGRILIN is not recommended in these circumstances (see section 4.5). 
Uporaba zdravila INTEGRILIN pri takšnih bolnikih torej ni priporočljiva (glejte poglavje 4.5).
During treatment with Integrilin in this study, minor bleeding was a very common complication (>1/10, or 13.1% for Integrilin versus 7.6% for placebo). 
Manjše krvavitve so bile v tej študiji med zdravljenjem z zdravilom Integrilin zelo pogost zaplet (> 1/10 ali 13,1 % za zdravilo Integrilin v primerjavi s 7,6 % za placebo).
If either a confirmed platelet decrease to < 100,000/mm3 or acute profound thrombocytopaenia is observed, discontinuation of each treatment medication having known or suspected thrombocytopenic effects, including eptifibatide, heparin and clopidogrel, should be considered immediately. 
Če se pojavi potrjeno zmanjšanje števila trombocitov na < 100.000 celic/mm3, ali akutna izrazita trombocitopenija, je treba nemudoma prekiniti uporabo zdravil, za katere je znano ali se domneva, da učinkujejo trombocitopenično, vključno z eptifibatidom, heparinom in klopidogrelom.
Ask your hospital pharmacist how to throw away medicines you no longer use. 
O načinu odstranjevanja zdravila, ki ga ne uporabljate več, se posvetujte z bolnišničnim farmacevtom.
4.5 Interaction with other medicinal products and other forms of interaction 
4.5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Varfarin in dipiridamol
− if you have or have had severe kidney or liver problems. 
− če imate ali ste kdaj imeli hude težave z ledvicami ali jetri;
(> 1 mm), 
p < 0,001).
Pharmacotherapeutic group: Antithrombotic agent (platelet aggregation inhibitors excl. heparin), ATC code: B01AC16 
Farmakoterapevtska skupina: Antitrombotična zdravila (zaviralci agregacije trombocitov z izjemo heparina), ATC oznaka: B01AC16
Thrombocytopaenia occurring after first exposure to a GPIIb/IIIa inhibitor may be explained by the fact that antibodies are naturally present in some normal individuals. 
Trombocitopenijo, ki se pojavi po prvi izpostavljenosti zaviralcu GPIIb/IIIa, se lahko pojasni s tem, da so protitelesa pri nekaterih zdravih osebah naravno prisotna.
Bleeding events were more frequent in patients receiving concurrent heparin while undergoing PCI, when ACT exceeded 350 seconds (see section 4.4, heparin use). 
Krvavitve so bile pogostejše pri bolnikih, ki so med perkutano koronarno intervencijo sočasno dobivali heparin, če je AČS presegal 350 sekund (glejte poglavje 4.4,
Incidence of Death/CEC-Assessed MI («Treated as Randomised» Population) 
Incidenca smrti oz. MI po oceni KKP (populacija “zdravljena v skladu z razporeditvijo v skupine”)
In the subgroup of patients undergoing PCI, major bleeding was observed commonly, in 9.7 % of Integrilin-treated patients vs. 4.6 % of placebo-treated patients. 
podskupini bolnikov, ki so jim naredili perkutano koronarno intervencijo, so bile večje krvavitve pogoste: pojavile so se pri 9,7 % zdravljenih z zdravilom Integrilin in 4,6 % prejemnikov placeba.
If percutaneous coronary intervention (PCI) is performed during Integrilin therapy, the intravenous solution may be continued for up to 96 hours. 
Če je bil med zdravljenjem z zdravilom Integrilin opravljen perkutani koronarni poseg (PCI), lahko intravenska infuzija traja do 96 ur.
− raised cardiac enzymes or markers (e.g. CK-MB, troponins) and 
- zvišanjem vrednosti srčnih encimov ali markerjev (npr. CK-MB, troponini), - srčnim popuščanjem.
What Integrilin looks like and contents of the pack Integrilin solution for infusion: 100 ml vial, pack of one vial. 
Izgled zdravila Integrilin in vsebina pakiranja Integrilin raztopina za infundiranje: 100 ml viala, pakiranje po ena viala.
Take special care with Integrilin: 
Bodite posebno pozorni pri uporabi zdravila Integrilin
4.4 Special warnings and precautions for use 
4.4 Posebna opozorila in previdnostni ukrepi Krvavitve
The infusion was continued until hospital discharge, until the time of coronary artery bypass grafting (CABG) or for up to 72 hours, whichever occurred first. 
Infuzijo so prejemali do odpusta iz bolnišnice, do koronarnega premostitvenega posega ali do preteka 72 ur, karkoli je nastopilo prej.
OTHER SPECIAL WARNING(S), IF NECESSARY Inspect the vial content. 
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA
To avoid the possibility of interactions with other medicines please tell your doctor or hospital pharmacist if you are taking or have recently taken or might take any other medicines, including medicines obtained without a prescription. 
Druga zdravila in zdravilo Integrilin Da bi se izognili morebitnemu medsebojnemu delovanju z drugimi zdravili, obvestite svojega zdravnika ali bolnišničnega farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katerokoli zdravilo, tudi če ste ga dobili brez recepta.
INTEGRILIN is compatible with 0.9 % sodium chloride solution for injection and with dextrose 5 % in Normosol R with or without potassium chloride. 
Zdravilo INTEGRILIN je združljivo z 0,9 % raztopino natrijevega klorida za injiciranje in s 5 % dekstrozo v Normosolu R, z ali brez kalijevega klorida.
If the patient weighs < 70 kg, a bolus dose of 60 units/kg is recommended, followed by an infusion of 12 units/kg/hr. 
Če pa je bolnikova telesna masa < 70 kg, uporabite bolusni odmerek 60 enot/kg, ki naj mu sledi infuzija 12 enot/kg/h.
Marketing Authorisation Holder and manufacturer Marketing Authorisation Holder: 
Imetnik dovoljenja za promet z zdravilom in izdelovalec Imetnik dovoljenja za promet z zdravilom:
INTEGRILIN is indicated for the prevention of early myocardial infarction in adults presenting with unstable angina or non-Q-wave myocardial infarction, with the last episode of chest pain occurring within 24 hours and with electrocardiogram (ECG) changes and/or elevated cardiac enzymes. 
Zdravilo INTEGRILIN je indicirano za preprečevanje zgodnjega miokardnega infarkta pri odraslih z nestabilno angino pektoris ali miokardnim infarktom brez zobca Q v elektrokardiogramu (EKG), ki so imeli zadnji napad bolečine v prsih v preteklih 24 urah ter imajo EKG spremembe, zvišano koncentracijo srčnih encimov ali oboje.
INTEGRILIN is compatible with 0.9 % sodium chloride solution for infusion and with dextrose 5 % in Normosol R with or without potassium chloride. 
Zdravilo INTEGRILIN je združljivo z 0,9 % raztopino natrijevega klorida za infundiranje in s 5 % dekstrozo v Normosolu R, z ali brez kalijevega klorida.
There is limited therapeutic experience with INTEGRILIN in patients for whom thrombolytic therapy is generally indicated (e.g. acute transmural myocardial infarction with new pathological Q-waves or elevated ST-segments or left bundle branch block in the ECG). 
Terapevtske izkušnje z uporabo zdravila INTEGRILIN so skope pri bolnikih, pri katerih je praviloma indicirano trombolitično zdravljenje (npr. tistih z akutnim transmuralnim miokardnim infarktom z novimi patološkimi zobci Q, zvišanjem spojnice ST ali levokračnim blokom v EKG).
Thrombocytopenia and Immunogencity related to GP IIb/IIIa inhibitors INTEGRILIN inhibits platelet aggregation, but does not appear to affect the viability of platelets. 
Trombocitopenija in imunogenost, povezani z zaviralci GP IIb/IIIa Zdravilo INTEGRILIN zavira agregacijo trombocitov, ni pa videti, da bi vplival na njihovo življenjsko dobo.
LIST OF EXCIPIENTS Citric acid monohydrate, sodium hydroxide, water for injections. 
SEZNAM POMOŽNIH SNOVI citronska kislina monohidrat, natrijev hidroksid in voda za injekcije.
The incidence of severe or life threatening bleeding events with Integrilin was 1.9% compared to 1.1% with placebo. 
Incidenca hudih ali smrtno nevarnih krvavitev je bila med uporabo zdravila Integrilin 1,9 % in med uporabo placeba 1,1 %.
In patients with moderate to severe renal insufficiency (creatinine clearance < 50 ml/min), the clearance of eptifibatide is reduced by approximately 50% and steady-state plasma levels are approximately doubled. 
Pri bolnikih z zmerno do hudo ledvično insuficienco (kreatininski očistek < 50 ml/min) je očistek eptifibatida za približno 50 % manjši, plazemske koncentracije v stanju dinamičnega ravnovesja pa so približno podvojene.
GlaxoSmithKline (Ireland) Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland Manufacturer: 
GlaxoSmithKline (Ireland) Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Irska Izdelovalec:
What Integrilin contains 
Kaj vsebuje zdravilo Integrilin
− history of stroke within 30 days or any history of haemorrhagic stroke 
- anamnezo možganske kapi v zadnjih 30 dneh ali anamnezo hemoragične kapi kadarkoli;
Before infusion of INTEGRILIN, the following laboratory tests are recommended to identify preexisting haemostatic abnormalities: prothrombin time (PT) and aPTT, serum creatinine, platelet count, haemoglobin and haematocrit levels. 
Za ugotavljanje obstoječih motenj hemostaze je pred začetkom infuzije zdravila INTEGRILIN priporočljivo opraviti naslednje laboratorijske preiskave: določanje protrombinskega časa (PČ) in aPTČ, kreatinina v serumu, števila trombocitov ter koncentracije hemoglobina in hematokrita.
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 1 vial of 10 ml 
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT 1 viala 10 ml
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 1 vial of 100 ml 
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT 1 viala 100 ml
Fatal bleeding (the majority involved central and peripheral nervous system disorders: cerebral or intracranial haemorrhages); pulmonary haemorrhage, acute profound thrombocytopenia, haematoma. 
Zelo redki smrtne krvavitve (večinoma je šlo za motnje osrednjega in perifernega živčevja: možganske ali intrakranialne krvavitve), pljučne krvavitve, akutna huda trombocitopenija, hematomi Bolezni imunskega sistema Zelo redki anafilaktične reakcije
MARKETING AUTHORISATION HOLDER 
Izkušnje po pridobitvi dovoljenja za promet
In patients undergoing CABG, the incidence of bleeding was not increased by Integrilin compared to the patients treated with placebo. 
Pri bolnikih z obvodom koronarne arterije incidenca krvavitev med uporabo zdravila Integrilin ni bila večja kot med uporabo placeba.
Integrilin is given into the vein by direct injection followed by an infusion (drip solution). 
Kako uporabljati zdravilo Integrilin Zdravilo Integrilin se daje z injekcijo v veno, temu pa sledi (kapalna) infuzija.
These plasma concentrations are achieved rapidly when the infusion is preceded by a 180 microgram/kg bolus. 
Plazemsko koncentracijo v tem območju lahko dosežete hitro, če pred infuzijo uporabite bolus 180 mikrogramov/kg.
GUSTO moderate or severe/life threatening bleeding occurred significantly more often with early routine eptifibatide (7.4% vs. 5.0% in delayed provisional eptifibatide group; p <0.001). 
Hude/smrtno nevarne krvavitve po GUSTO so se pojavile značilno pogosteje med zgodnjo rutinsko uporabo eptifibatida (7,4 % v prim.
In patients with moderate renal impairment, (creatinine clearance 30 - 50mL/min) 100% inhibition was achieved at 24 hours following administration of 2 microgram/kg/min. 
Pri bolnikih z zmerno okvaro ledvic (kreatininski očistek od 30 do 50 ml/min) je bila 100 % inhibicija dosežena 24 ur po uporabi 2 mikrograma/kg/min.
Integrilin should not be used if it is noticed that particulate matter or discoloration is present. 
Ne uporabljajte zdravila Integrilin, če ste opazili delce ali obarvanje vsebine.
− serious bleeding (for example, bleeding inside the abdomen, inside the brain, and into the lungs). 
- hude krvavitve (na primer, krvavitve v trebušni votlini, možganih ali v pljuča);
Protection of INTEGRILIN solution from light is not necessary during administration. 
Zaščita raztopine Integrilin pred svetlobo med uporabo ni potrebna.
Arterial sheaths may be removed when coagulation has returned to normal (e.g. when activated clotting time (ACT) is less than 180 seconds (usually 26 hours after discontinuation of heparin). 
ko je aktivirani čas strjevanja (AČS) manjši od 180 sekund; ponavadi 2 do 6 ur po ukinitvi heparina).
Keep this medicine out of the sight and reach of children Do not use this medicine after the expiry date (EXP) stated on the package and the vial. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in na viali poleg oznake »EXP«.